TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
Rhea-AI Summary
TransMedics (Nasdaq: TMDX) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The TransMedics management team is scheduled to present at 2:00 p.m. ET / 1:00 p.m. CT. A live and archived webcast of the fireside chat, along with the company’s standard investor presentation, will be accessible via the Investors section of the TransMedics website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | earnings date notice | Neutral | -4.2% | Announced Q2 2026 results date; shares fell 4.16% over the following 24 hours. |
| Jul 06 | strategic investment | Positive | +3.4% | Completed PAD Aviation investment to support European transplant logistics expansion. |
| May 21 | inducement equity grants | Neutral | +0.1% | Granted equity awards to 14 new employees under Nasdaq listing rules. |
| May 19 | growth conference presentation | Neutral | +2.8% | Announced William Blair conference participation; shares rose 2.83% over 24 hours. |
| May 05 | first-quarter earnings | Positive | -23.2% | Reported $173.9M revenue and reiterated guidance; shares fell 23.19% over 24 hours. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mostly divergent from the apparent announcement sentiment, with four divergences and one alignment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
Hannah Jeffrey
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-302836981.html
SOURCE TransMedics Group, Inc.